Want to see IPSC full AI Analyst Report?
Century Therapeutics (IPSC) Drug Pipeline
| Drug Name | Condition | Stage | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Il-2, Cnty-101, Lymphodepleting Chemotherapy | Lupus Nephritis, Systemic Lupus Erythematosus, Diffuse Cutaneous Systemic Sclerosis, Idiopathic Inflammatory Myopathies | Phase I | Recruiting | A Study of CNTY-101 in Participants With Refractory B Cell-mediated Autoimmune Diseases | Feb 05, 2024 | ― |
| Il-2, Cnty-101, Lymphodepleting Chemotherapy | Indolent Non-Hodgkin Lymphoma, R/R Cd19-Positive B-Cell Malignancies, Aggressive Non-Hodgkin Lymphoma | Phase I | Active Not Recruiting | A Study of CNTY-101 in Participants With CD19-Positive B-Cell Malignancies | Apr 08, 2022 | ― |
| Drug Name | Stage | Condition | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Il-2, Cnty-101, Lymphodepleting Chemotherapy | Phase I | Lupus Nephritis, Systemic Lupus Erythematosus, Diffuse Cutaneous Systemic Sclerosis, Idiopathic Inflammatory Myopathies | Recruiting | A Study of CNTY-101 in Participants With Refractory B Cell-mediated Autoimmune Diseases | Feb 05, 2024 | ― |
| Il-2, Cnty-101, Lymphodepleting Chemotherapy | Phase I | Indolent Non-Hodgkin Lymphoma, R/R Cd19-Positive B-Cell Malignancies, Aggressive Non-Hodgkin Lymphoma | Active Not Recruiting | A Study of CNTY-101 in Participants With CD19-Positive B-Cell Malignancies | Apr 08, 2022 | ― |
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Century Therapeutics, Inc. (IPSC) have in its pipeline
Century Therapeutics IPSC is currently developing the following drugs: Il-2, Cnty-101, Lymphodepleting Chemotherapy. These drug candidates are in various stages of clinical development as the company works toward FDA approval.